Comparative field efficacy of all-in-one intradermal vaccine based on an inactivated recombinantwith an embedded/integrated porcine circovirus type 2 (PCV2) capsid protein and concurrent administration with monovalent ofand PCV2 intradermal vaccine.

Abstract

BACKGROUND: Efficacy of an intradermal all-in-one vaccine based on an inactivated recombinantstrain with an embedded/integrated porcine circovirus type 2 (PCV2) capsid protein thereof, as the single active substance, is provided. OBJECTIVE: To evaluate and compare an intradermaland PCV2 all-in-one vaccine with monovalent ofand PCV2 intradermal vaccines administered concurrently. ANIMALS: A total of 60 pigs were randomly divided into three groups (20 pigs per group; male =10 and female = 10) in each of three farms. METHODS: The clinical field trials were conducted on three farms, each suffering from PCV2 infection and enzootic pneumonia. The pigs in the all-in-one-vaccinated groups were injected intradermally with 0.2 mL of the all-in-one vaccine through a needle-free device. The pigs in the concurrent-vaccinated groups were injected with 0.2 mL of PCV2 vaccine and 0.2 mL ofvaccine intradermally through a needle-free device, which allows two vaccines each in their separate vials to be applied simultaneously. The pigs in the unvaccinated groups were administered an equal volume of phosphate buffered saline in the same manner at 21 days of age. RESULTS: Intradermal vaccination improved pig production performance. It was also able to stimulate systemic humoral and cell-mediated immune responses toand PCV2d, which reducednasal loads and the severity of mycoplasmal lung lesions. Through this stimulation, PCV2 blood viral load and lymphoid severity were also reduced. DISCUSSION: The intradermal vaccines were considered efficacious and conferred cross-protection of pig herds suffering from PCV2 infection and enzootic pneumonia.